# A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

> **NCT01564784** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 326 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** inotuzumab ozogamicin
- **DRUG:** FLAG (fludarabine, cytarabine and G-CSF)
- **DRUG:** HIDAC (high dose cytarabine)
- **DRUG:** cytarabine and mitoxantrone

## Key facts

- **NCT ID:** NCT01564784
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-02
- **Primary completion:** 2016-03-08
- **Final completion:** 2017-01-04
- **Target enrollment:** 326 (ACTUAL)
- **Last updated:** 2019-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01564784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01564784, "A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01564784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*